로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Glycoprotein E (VZV)

Glycoprotein E (VZV)

요약

Name:Envelope (E) protein
Target Synonym:gE-1,Envelope glycoprotein E,gE
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

제품 리스트 구매

Glycoprotein E (VZV) 分子别名

gE

Glycoprotein E (VZV) 分子背景

Varicella-zoster virus (VZV) is a neurotropic virus belonging to the Herpesviridae family. Primary VZV infection causes chickenpox and is followed by a life-long latent infection established mainly in the cranial and dorsal root ganglia. Reactivation of the virus is often associated with shingles (herpes zoster). Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.

Glycoprotein E (VZV) 前沿进展

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
LHF-535 LHF-535; LHF-535-SDD Phase 1 Clinical Kineta Inc Details
SAR-440894 SAR-440894 Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) Chikungunya Fever Details
LHF-535 LHF-535; LHF-535-SDD Phase 1 Clinical Kineta Inc Details
SAR-440894 SAR-440894 Phase 1 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) Chikungunya Fever Details

This web search service is supported by Google Inc.

totop